Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study

Heparins and vitamin K antagonists are the mainstay of treatment of splanchnic vein thrombosis (SVT). Rivaroxaban is a potential alternative, but data to support its use are limited. We aimed to evaluate the safety and efficacy of rivaroxaban for the treatment of acute SVT. In an international, sing...

Descripción completa

Detalles Bibliográficos
Autores principales: Ageno, Walter, Beyer Westendorf, Jan, Contino, Laura, Bucherini, Eugenio, Sartori, Maria Teresa, Senzolo, Marco, Grandone, Elvira, Santoro, Rita, Carrier, Marc, Delluc, Aurélien, De Stefano, Valerio, Pomero, Fulvio, Donadini, Marco Paolo, Tosetto, Alberto, Becattini, Cecilia, Martinelli, Ida, Nardo, Barbara, Bertoletti, Laurent, Di Nisio, Marcello, Lazo-Langner, Alejandro, Schenone, Alessandro, Riva, Nicoletta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631568/
https://www.ncbi.nlm.nih.gov/pubmed/35439303
http://dx.doi.org/10.1182/bloodadvances.2022007397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631568/
https://www.ncbi.nlm.nih.gov/pubmed/35439303
http://dx.doi.org/10.1182/bloodadvances.2022007397

Ejemplares similares